Abstract:Depression disorder is one of the most serious mental illnesses in the world. Escitalopram is the essential first-line medication for depression disorder. It is the substrate of hepatic cytochrome P450 (CYP) enzyme CYP2C19 with high polymorphism. The effect of CYP2C19 on pharmacokinetics and pharmacodynamics on Caucasian population has been studied. The Clinical Pharmacogenetics Implementation Consortium Guideline provides dosing recommendations for escitalopram on CYP2C19 genotypes on the basis of the studies on Caucasian population. However, the gene frequency of the alleles of CYP2C19 showed racial differences between Chinese and Caucasian populations. Representatively, the frequency of the *2 and *3 allele, which were considered as poor metabolizer, has been shown to be three times higher in Chinese than in Caucasians. In addition, the environments might also lead to different degrees of impacts on genotypes. Therefore, the guidelines based on the Caucasians may not be applicable to the Chinese, which induced the establishment of a guideline in China. It is necessary to provide the evidence of individual treatment of escitalopram in Chinese by studying the effect of CYP2C19 genotypes on the pharmacokinetics parameters and steady-state concentration on Chinese. In this study, single-center, randomized, open-label, two-period, two-treatment crossover studies were performed. Ninety healthy Chinese subjects finished the trials, and they were included in the statistical analysis. The pharmacokinetics characteristics of different genotypes in Chinese were obtained. The results indicate that the poor metabolizer had higher exposure, and increased half-life than the extensive metabolizer and intermediate metabolite. The prediction of steady-state concentration based on the single dose trial on escitalopram shows that the poor metabolizer might have a higher steady-state concentration than the extensive metabolizer and intermediate metabolite in Chinese. The results indicate that the genetic testing before medication and the adjustment of escitalopram in the poor metabolizer should be considered in the clinical treatments in Chinese. The results provide the evidence of individual treatment of escitalopram in Chinese, which will be beneficial for the safer and more effective application of escitalopram in the Chinese population. Clinical Trial Registration : identifier ChiCTR1900027226.

Effect of Cyp2d6 Genetic Polymorphism on the Metabolism of Citalopram in Vitro

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

The Cytochrome P450 2D6 (CYP2D6) Enzyme Polymorphism: Screening Costs and Influence on Clinical Outcomes in Psychiatry

Effect of CYP2D6 Variants on Venlafaxine Metabolism in Vitro

Effects of 22 Novel CYP2D6 Variants Found in Chinese Population on the Metabolism of Dapoxetine

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.

Effects of 31 Recombinant CYP2C19 Variants on Clomipramine Metabolism in Vitro

Effects of CYP2C19 Variants on Fluoxetine Metabolism in Vitro.

Functional Measurement Of Cyp2c9 And Cyp3a4 Allelic Polymorphism On Sildenafil Metabolism

Effects of 24 CYP2D6 Variants Found in Chinese Population on the Metabolism of Clonidine in Vitro

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

Functional Characterization of 22 Novel Cyp2d6 Variants for the Metabolism of Tamoxifen

Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro

Evaluation of 24 CYP2D6 Variants on the Metabolism of Nebivolol In Vitro.

CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population

Effect of CYP2C9 Genetic Polymorphism on the Metabolism of Flurbiprofen in Vitro.

Effect of 24 Cytochrome P450 2D6 Variants Found in the Chinese Population on the N-demethylation of Amitriptyline in Vitro.

Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro

Characterizing the Effect of Cytochrome P450 (cyp)2c8, Cyp2c9, and Cyp2d6 Genetic Polymorphisms on Stereoselective N-Demethylation of Fluoxetine

Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms in Vitro